

BioCLIA Autoimmune Calibrator Set, gp210

| Cat.No. | Kit Size |
|---------|----------|
| MY00216 | 2 X 1 mL |
| MY00267 | 4 X 1 mL |

INTENDED USE

The BioCLIA Autoimmune Calibrator Set, gp210 is intended for the calibration of the BioCLIA gp210 performed on the BioCLIA 6500 and BioCLIA 500.

For professional *in vitro* diagnostic use only.

SUMMARY AND EXPLANATION

Autoimmune liver diseases (ALD) include autoimmune hepatitis (AIH),^{1,2} primary biliary cirrhosis (PBC)³ and primary sclerosing cholangitis (PSC).⁴ Determination of indicators such as AMA, CENP-B, LKM-1 and SLA/LP has significant correlation to ALD diagnosis.

Anti-gp210 antibodies can specifically bind to a 210 kDa transmembrane glycoprotein on the nuclear pore complex in the 15 amino acid residues of gp210 carboxyl terminal. Anti-gp210 antibody detection has important value for PBC diagnosis for the patients with suspected clinical, biochemical and histologic findings but anti-mitochondrial antibodies (AMAs) negative, or the ones with AMAs positive but not typical in clinical syndromes. It is present approximately 25%~30% in PBC patients.^{5,6,7,8}

MATERIALS SUPPLIED

- **gp210 Calibrator 1** Barcode labeled tubes with buffer containing human antibodies to gp210 in stabilizers and preservatives. Ready to use, 1 mL.



Preservatives: 0.0015% < Proclin 300 < 0.6%.

- **gp210 Calibrator 2** Barcode labeled tubes with buffer containing human antibodies to gp210 in stabilizers and preservatives. Ready to use, 1 mL.



Preservatives: 0.0015% < Proclin 300 < 0.6%.

The Calibrator Code contains calibrators' information is provided in each kit.

WARNINGS AND PRECAUTIONS

- For professional *in vitro* diagnostic use only.
- Do not use any calibrators beyond their expiration dates.
- Do not mix calibrators from different lots unless specified.
- Instructions must be carefully followed for using and storing of calibrators. Any modification in procedure may interfere with the results.
- Calibrators and contaminated vials must be handled strictly following safety guidelines or rules of biological hazards to ensure the users' and environmental safety.
- Any serious incident that has occurred in relation to the device

shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established!

Precautions:



Human serum is added in the calibrators.

- The human derived material in this product was tested by FDA approved methods and found nonreactive for Hepatitis B Surface Antigen (HBsAg), Anti-HCV and HIV 1/2 antibodies. Handle as if potentially infectious.⁷ Avoid contacting with skin and eyes. Do not empty into drains. Wear suitable protective gloves and clothing.



- Proclin 300 is added in the calibrators at concentration between 0.0015% - 0.6%.
- Calibrators contain chemical and biological components. Avoid ingesting or splashing onto skin and mucous membrane. If direct contact with calibrators happens, rinse immediately the contact surface with plenty of water and see a doctor if necessary.

STORAGE CONDITIONS

- Store the kit at 2-8 °C.
- The shelf life of the unopened kit is 12 months from day of production.
- Vial opened calibrators could be used for 28 successive days, exposure no more than 2 hours each time when kept uncapped and is good for up to 20 calibrations, after which the reagent must be discarded.
- Avoid repeated freezing and thawing.

ASSAY PROCEDURE

Detailed information about operating the BioCLIA instruments can be taken from the Instrument User's Manual.

Note that, it is important to perform all routine maintenance procedures for optimal performance.

Assay Calibration

The BioCLIA Autoimmune Reagent Kit utilizes a predefined lot specific Master Curve which is uploaded into the instrument via the barcode provided in the main reagent kit. The Calibrator Code contains calibrator information is then scanned. Based on the results of running two calibrators, the instrument specific Working Calibration Curve is generated and is used to calculate the concentration from

the RLU obtained for each patient.

For each new lot of reagent, please calibrate prior to the first time use, and every 28 days thereafter. The software will not allow the lot to be used if the above requirements are not met.

Programming and Running samples

- Put the kit into the corresponding position of the reagent chamber of the fully automatic chemiluminescence analyzer. The information of the kit can be uploaded into the instrument system through the scanning of reagent barcode, and can also be set through the supporting software of the instrument.
- The information of calibrator / quality control is identified by scanning the calibrator / control barcodes, and the position of calibrator / quality control is assigned in the instrument system.
- The sample to be tested is placed on the instrument sample rack chamber, and the corresponding test information is edited through the instrument supporting software.
- Start the operation procedure, and all calibrator / quality control / sample processing steps will be automatically executed.

TRACEABILITY

The reported values were determined over multiple runs on the BioCLIA 6500 and BioCLIA 500 using specific lots of reagents against an in-house standard. DGP IgA results are reported in RU/mL which is interpreted from relative light unit (RLU). Method comparison test showed good sensitivity and specificity of tested assay.

LIMITATIONS

- The calibrators are designed for calibration of the same lot of BioCLIA Autoimmune Reagent Kit.
- The calibrators can be kept uncapped onboard the instrument up to 2 hours for each time of usage. And a total up to 20 calibrations are suggested, for any longer period of time, the reagent should be discarded, otherwise may result in improper calibration of the assay and which can give improper results.

SYMBOLS

| | | | |
|--|------------------------------------|--|---|
| | Catalog Number | | Use-by date |
| | In Vitro diagnostic medical device | | Lot Number |
| | Store between +2°C and +8°C | | Consult Instruction for Use |
| | Manufacturer | | Authorized Representative in the European Community |
| | CE Marking | | Contains Sufficient for <n> Tests |
| | Biological Risk | | GHS07 Warning |
| | Calibrator 1 | | |
| | Calibrator 2 | | |

REFERENCE

- Czaja AJ. Autoimmune liver disease. Current Opinion in Gastroenterology 2007;23:255-62.

- Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli - Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213.
- Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti - gp210 and anti - centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27.
- T Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert review of gastroenterology & hepatology 2013;7:103-14.
- ITOH S, ICHIDA T, YOSHIDA T, HAYAKAWA A, UCHIDA M, TASHIRO - ITOH T, et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. Journal of gastroenterology and hepatology 1998;13:257-65.
- Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T, Ueki T, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. Journal of hepatology 2005;42:386-92.
- Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, et al. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. Journal of autoimmunity 2006;26:138-45
- Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti - gp210 and anti - centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27.
- Richmond JY, Mckinney RW. Biosafety in microbiological and biomedical laboratories: U.S.GPO. 1999.



HOB Biotech Group Corp., Ltd.
C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park,
Suzhou, Jiangsu, 215123, China

CONTACT INFORMATION:

TEL (+86)512-69561996

Fax (+86)512-62956652

WEBSITE: www.hob-biotech.com

CUSTOMER SERVICE: HOB Biotech Group Co., Ltd

CUSTOMER SERVICE: TEL (+86)4008601202



EUROPE REPRESENTATIVE: Emergo Europe

ADDRESS/LOCATION :

Prinsessegracht 20, 2514 AP The Hague, The Netherlands



The eIFU is available on Website:

<http://en.hob-biotech.com/usercenter/login.aspx>

TECHNICAL ASSISTANCE

For technical assistance, contact your National Distributor.

Date of issue: 17th March 2019

Date of revision: 20th December 2021

Change Control Number: CN21129E

Version: A/1 (EN)